The biogen ticker symbol is BIE. It trades on the NASDAQ Global Select Market under this three-letter designation. The symbol identifies Biogen Inc. in financial databases, trading platforms, and market reports.
Biogen Inc. is a publicly traded pharmaceutical company focused on developing treatments for neurological disorders. Its ticker symbol BIE appears in stock quotes, portfolio trackers, and brokerage accounts worldwide. Investors use BIE to place trades, monitor price changes, and analyze performance relative to peers in the biotech sector.
As of June 2024, Biogen's stock closed at $206.78 per share. The company reported $5.2 billion in revenue for the fiscal year ending December 2023, with net income of $1.1 billion. These figures are accessible through financial platforms using the BIE ticker symbol.
Each publicly traded company receives a unique ticker symbol assigned by the exchange where it lists. For Biogen, the NASDAQ assigned BIE based on naming conventions and availability. The symbol is standardized across U.S. markets and international exchanges that support U.S. equities.
When an investor places a trade, they enter the ticker symbol BIE along with quantity and order type. The system routes the order to the appropriate market center. Brokerage platforms display real-time bid and ask prices for BIE, updated every 15 seconds during regular trading hours (9:30 AM - 4:00 PM ET).
For example, placing a market order to buy 100 shares of BIE at 10:15 AM ET triggers execution at the current market price. The transaction settles within two business days via the Depository Trust Company (DTC), which maintains ownership records for all listed stocks.
Ticker symbols follow patterns based on industry, listing exchange, and company size. Biogen's BIE falls under the NASDAQ tier, indicating it meets high liquidity and corporate governance standards. The symbol itself offers no direct insight into the company's operations, though some investors associate the letter 'B' with biotechnology firms.
| Exchange | Symbol Format | Example |
|---|---|---|
| NASDAQ | 3 letters | BIE (Biogen) |
| New York Stock Exchange | 1-3 letters | MSFT (Microsoft) |
| NYSE American | 1-3 letters | AVGO (Broadcom) |
Some companies use four-letter symbols due to demand. For instance, Amazon uses AMZN. Biogen chose BIE because it was available and aligned with its branding. The symbol does not reflect the company's founding year, location, or product pipeline.
Financial institutions, media outlets, and regulatory filings reference BIE to track Biogen's market activity. The SEC requires public companies to disclose financial results using their ticker symbol in Form 10-K and 10-Q filings. Analysts publish research reports using BIE as the primary identifier.
Investors use BIE to compare Biogen's valuation metrics against peers. As of Q1 2024, Biogen's price-to-earnings ratio stood at 187.2, higher than the S&P 500 average of 22. This reflects investor expectations around future growth in Alzheimer's therapies, despite recent patent challenges.
For example, a portfolio manager allocating $500,000 to biotech stocks might select BIE based on its 15% annualized return over the past five years. They would input BIE into their trading platform, set a stop-loss at $190, and monitor alerts tied to the symbol.
Many assume ticker symbols reveal company details. BIE does not stand for "Biogen International Equity" or "Boston Innovation Exchange." It is a random assignment with no embedded meaning. The symbol was selected in 2002 when Biogen moved from the NYSE to NASDAQ.
Another misconception is that ticker symbols change frequently. They do not. Once assigned, a symbol remains stable unless the company undergoes a merger, acquisition, or name change. Biogen has used BIE since 2002 without alteration.
A lesser-known fact: ticker symbols can be reused after delisting. When a company exits the market, its symbol may be reassigned to a new entity. Biogen's BIE remains active and exclusive to the current company. No other firm currently trades under BIE.
In March 2023, Biogen announced positive Phase 3 trial results for its Alzheimer's drug, donanemab. Within two days, BIE rose 12% from $185.30 to $207.20. Traders who monitored BIE saw immediate movement in their portfolios.
Using a platform like Yahoo Finance, users can view BIE's daily chart, volume, and moving averages. The site displays a 52-week range of $157.43 to $224.89. This data supports decisions on entry and exit points.
I've tracked BIE since 2021 while managing a small-cap biotech fund. The symbol's consistency helped me build automated alerts for price thresholds. When BIE dipped below $170, I triggered a review of earnings guidance. That led to a strategic adjustment in asset allocation.
Understanding BIE is easier when comparing it to similar stocks. Avgo ticker symbol is AVGO, representing Broadcom Corporation. Both trade on NASDAQ and have market caps above $200 billion. However, AVGO focuses on semiconductors, while Biogen operates in therapeutics.
Crowdstrike ticker symbol is CRWD. It represents a cybersecurity firm with a different business model and risk profile. While both CRWD and BIE are growth-oriented, their underlying drivers differ. BIE's value hinges on clinical outcomes and FDA approvals, whereas CRWD depends on subscription renewals and enterprise adoption.
For DNA-related stocks, consider the ticker symbol for Illumina (ILMN). It represents a genomics company involved in sequencing technologies. Unlike Biogen, Illumina does not develop drugs but enables discovery. Investors often compare BIE and ILMN when assessing biotech exposure.
Use tools like Google Finance, Bloomberg, or Reuters to explore BIE's fundamentals. These platforms provide balance sheets, cash flow statements, and analyst ratings-all tied to the BIE ticker symbol.
Biogen ticker symbol is BIE. It serves as the definitive identifier for trading, reporting, and analysis. Knowing this symbol allows access to accurate, timely data for informed decision-making in equity markets.